These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26166081)

  • 1. Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer.
    Yu J; Xiao J; Yang Y; Cao B
    Medicine (Baltimore); 2015 Jul; 94(27):e1072. PubMed ID: 26166081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
    Rajeswaran A; Trojan A; Burnand B; Giannelli M
    Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
    Griesinger F; Korol EE; Kayaniyil S; Varol N; Ebner T; Goring SM
    Lung Cancer; 2019 Sep; 135():196-204. PubMed ID: 31446995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
    Raez LE; Kobina S; Santos ES
    Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin doublets in non-small cell lung cancer: a literature review.
    Cortinovis D; Bidoli P; Zilembo N; Fusi A; Bajetta E
    Lung Cancer; 2008 Jun; 60(3):325-31. PubMed ID: 18440088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.
    Rossi A; Di Maio M; Chiodini P; Rudd RM; Okamoto H; Skarlos DV; Früh M; Qian W; Tamura T; Samantas E; Shibata T; Perrone F; Gallo C; Gridelli C; Martelli O; Lee SM
    J Clin Oncol; 2012 May; 30(14):1692-8. PubMed ID: 22473169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy analysis of third-generation plus platinum doublets in the first-line chemotherapy of advanced non-small cell lung cancer].
    Zhao LD; Zhang XR; Li JL; Wang ZP; Wang Y; Hao XZ; Hu XS; Zhou SY; Sun Y; Shi YK
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(22):1527-31. PubMed ID: 22944054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.
    Cortellini A; Gambale E; Cannita K; Brocco D; Parisi A; Napoleoni L; Masedu F; Irtelli L; De Tursi M; Natoli C; Ficorella C
    Thorac Cancer; 2018 Feb; 9(2):241-252. PubMed ID: 29388383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia.
    Zhang XF; De-Sheng LV; Li M; Sun GE; Liu CH
    Indian J Cancer; 2017; 54(1):104-114. PubMed ID: 29199672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
    Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
    Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
    Chang Q; Zhang Y; Xu J; Zhong R; Qiang H; Zhang B; Han B; Qian J; Chu T
    Thorac Cancer; 2019 May; 10(5):1043-1050. PubMed ID: 30900826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
    Scagliotti GV; Kortsik C; Dark GG; Price A; Manegold C; Rosell R; O'Brien M; Peterson PM; Castellano D; Selvaggi G; Novello S; Blatter J; Kayitalire L; Crino L; Paz-Ares L
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):690-6. PubMed ID: 15701857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of prognostic factors affecting efficacy in carboplatin- and paclitaxel-based first-line chemotherapies for advanced non-small-cell lung cancer.
    Komuro M; Kaneko M; Narukawa M
    Tumori; 2015; 101(4):424-32. PubMed ID: 25908047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum rechallenge in patients with advanced NSCLC: a pooled analysis.
    Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Ardine M; Barni S
    Lung Cancer; 2013 Sep; 81(3):337-342. PubMed ID: 23891507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
    Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.
    Zhao S; Gao F; Zhang Y; Zhang Z; Zhang L
    Int J Cancer; 2018 Apr; 142(8):1676-1688. PubMed ID: 29171009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.